Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRaCTICAL: Aflibercept in iPCV vs CSR vs nAMD
NCT02681783Phase 4Unknown
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- Dec 2018
- Primary completion
- Dec 2022
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of aflibercept in neovascular age-related macular degeneration (NVAMD), Central Serous Chorioretinopathy (CSCR), polypoidal choroidal vasculopathy (PCV), sponsored by Sunnybrook Health Sciences Centre. Status: unknown.
02
Drugs
aflibercept
03
Conditions
neovascular age-related macular degeneration (NVAMD)Central Serous Chorioretinopathy (CSCR)polypoidal choroidal vasculopathy (PCV)
Beyond the preview
Go deeper on NCT02681783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02681783.